2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Matthew J. Ellis from Washington University on Measuring Endocrine Therapy Efficacy With Ki67
Matthew J. Ellis, MD, PhD, director, Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, MO, discusses determining the efficacy of endocrine therapy by measuring the Ki67 cell-proliferation marker after a few weeks of receiving therapy.
Ellis explains that endocrine therapy resistant ER-positive disease is the highest cause of deaths in breast cancer. By finding tumors that do not respond to endocrine therapy early on by using the Ki67 marker you can change therapies early in the treatment process.